Abstract

SERRANO, Manuel; ESPINOSA, Gerard; CERVERA, Ricard  and  SERRANO, Antonio. COVID-19 coagulopathy and antiphospholipid syndrome. Rev.Colomb.Reumatol. [online]. 2022, vol.29, suppl.1, pp.25-34.  Epub Feb 02, 2024. ISSN 0121-8123.  https://doi.org/10.1016/j.rcreu.2021.02.013.

The presence of thrombotic events in COVID-19 patients has been described since the beginning of the pandemic. This association has been confirmed in most of the reported studies. Autopsy reports have shown that most thromboses are located in the lung, although they have also been observed in other organs such as the skin and kidneys. SARS-CoV2 infection induces a generalized prothrombotic state, which is attributed to a combination of factors such as hypoxia, excess cellular apoptosis, and mainly to overactivation of the immune system. Among immune-mediated prothrombotic situations, antiphospholipid syndrome (APS) stands out. Recurrent thrombotic events are observed in APS in the presence of antiphospholipid antibodies (aPL). There are numerous studies that report high prevalence of aPL in patients with COVID-19 infection. However, the results show discrepancies in the data on the prevalence of aPL, and its role in the pathogenesis of thrombosis in these patients. This could be due to the heterogeneity of the detection procedures for aPL or to transient elevations of non-pathogenic aPL levels in the context of infection. In this review we try to clarify the role of aPL in COVID-19 infection, and attempt to answer the question of whether it is a coagulopathy of its own, or secondary to APS.

Keywords : Antiphospholipid syndrome; Antibodies; antiphospholipid; Beta 2-glycoprotein; Cardiolipins; Lupus anticoagulant; Thrombosis; COVID-19; SARS-CoV-2; Coagulopathy.

        · abstract in Spanish     · text in English     · English ( pdf )